MX2024010646A - Anticuerpos anti-cd39 y uso de los mismos. - Google Patents
Anticuerpos anti-cd39 y uso de los mismos.Info
- Publication number
- MX2024010646A MX2024010646A MX2024010646A MX2024010646A MX2024010646A MX 2024010646 A MX2024010646 A MX 2024010646A MX 2024010646 A MX2024010646 A MX 2024010646A MX 2024010646 A MX2024010646 A MX 2024010646A MX 2024010646 A MX2024010646 A MX 2024010646A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- inhibit
- human
- methods
- enzymatic activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2022/079021 WO2023164872A1 (en) | 2022-03-03 | 2022-03-03 | Anti-cd39 antibodies and use thereof |
| CN2022126070 | 2022-10-19 | ||
| PCT/CN2023/079295 WO2023165561A1 (en) | 2022-03-03 | 2023-03-02 | Anti-cd39 antibodies and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010646A true MX2024010646A (es) | 2024-09-19 |
Family
ID=87883061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010646A MX2024010646A (es) | 2022-03-03 | 2023-03-02 | Anticuerpos anti-cd39 y uso de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11970543B2 (https=) |
| EP (1) | EP4486785A1 (https=) |
| JP (2) | JP7712496B2 (https=) |
| KR (1) | KR20240156633A (https=) |
| CN (2) | CN119569881B (https=) |
| AR (1) | AR128688A1 (https=) |
| AU (1) | AU2023227964A1 (https=) |
| CA (1) | CA3253669A1 (https=) |
| CL (1) | CL2024002620A1 (https=) |
| IL (1) | IL315351A (https=) |
| MX (1) | MX2024010646A (https=) |
| TW (1) | TW202340243A (https=) |
| WO (1) | WO2023165561A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023402712A1 (en) * | 2022-12-01 | 2025-05-08 | Innate Pharma | Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies |
| CN117986364B (zh) * | 2023-12-27 | 2025-01-21 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3153526T3 (da) * | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
| WO2012085132A1 (en) | 2010-12-22 | 2012-06-28 | Orega Biotech | Antibodies against human cd39 and use thereof |
| WO2016073845A1 (en) * | 2014-11-07 | 2016-05-12 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| EP3380519A1 (en) | 2015-11-23 | 2018-10-03 | Innate Pharma | Cd39 vascular isoform targeting agents |
| US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
| EP3452092B1 (en) | 2016-05-06 | 2020-08-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml) |
| WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| IL316357A (en) | 2017-07-31 | 2024-12-01 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| WO2019068907A1 (en) | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| SG11202002195YA (en) | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
| MX394121B (es) | 2018-03-14 | 2025-03-24 | Surface Oncology Inc | Anticuerpos que se unen a cd39 y sus usos |
| KR20210031694A (ko) | 2018-06-14 | 2021-03-22 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 엑토뉴클레오티다제 억제 및 항체-매개된 표적 사이토시스를 통한 t-세포 고갈을 예방 또는 역전시키는 조성물 및 방법 |
| MX2020012107A (es) | 2018-06-18 | 2021-01-29 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| US20230242660A1 (en) | 2019-02-21 | 2023-08-03 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies |
| KR20220061977A (ko) | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
| CN112714768B (zh) * | 2019-08-27 | 2025-02-18 | 科望(苏州)生物医药科技有限公司 | 新型抗cd39抗体 |
| US20220372160A1 (en) | 2019-09-16 | 2022-11-24 | Surface Oncology, Inc. | Anti-CD39 Antibody Compositions and Methods |
| CN110407941B (zh) | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| WO2021203058A2 (en) | 2020-04-03 | 2021-10-07 | Trishula Therapeutics, Inc. | Combination therapy involving anti-cd39 antibodies and adoptive cell therapy |
| KR20230065974A (ko) | 2020-09-10 | 2023-05-12 | 퓨리노미아 바이오테크, 아이엔씨. | NTPDase3의 표적화를 통해 항종양 면역 반응을 강화하기 위한 방법 및 조성물 |
| US20230416394A1 (en) | 2020-11-27 | 2023-12-28 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
-
2023
- 2023-03-02 WO PCT/CN2023/079295 patent/WO2023165561A1/en not_active Ceased
- 2023-03-02 AU AU2023227964A patent/AU2023227964A1/en active Pending
- 2023-03-02 CN CN202411518282.4A patent/CN119569881B/zh active Active
- 2023-03-02 CA CA3253669A patent/CA3253669A1/en active Pending
- 2023-03-02 IL IL315351A patent/IL315351A/en unknown
- 2023-03-02 CN CN202380024645.6A patent/CN119173535A/zh active Pending
- 2023-03-02 US US18/177,729 patent/US11970543B2/en active Active
- 2023-03-02 KR KR1020247032745A patent/KR20240156633A/ko active Pending
- 2023-03-02 JP JP2024552127A patent/JP7712496B2/ja active Active
- 2023-03-02 MX MX2024010646A patent/MX2024010646A/es unknown
- 2023-03-02 AR ARP230100529A patent/AR128688A1/es unknown
- 2023-03-02 TW TW112107685A patent/TW202340243A/zh unknown
- 2023-03-02 EP EP23762959.7A patent/EP4486785A1/en active Pending
-
2024
- 2024-03-25 US US18/616,056 patent/US20250084178A1/en active Pending
- 2024-09-02 CL CL2024002620A patent/CL2024002620A1/es unknown
-
2025
- 2025-07-10 JP JP2025116414A patent/JP2025148452A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025148452A (ja) | 2025-10-07 |
| KR20240156633A (ko) | 2024-10-30 |
| JP2025508956A (ja) | 2025-04-10 |
| AU2023227964A1 (en) | 2024-09-19 |
| IL315351A (en) | 2024-11-01 |
| EP4486785A1 (en) | 2025-01-08 |
| CA3253669A1 (en) | 2023-09-07 |
| WO2023165561A1 (en) | 2023-09-07 |
| US11970543B2 (en) | 2024-04-30 |
| CN119569881A (zh) | 2025-03-07 |
| US20240034803A1 (en) | 2024-02-01 |
| CN119569881B (zh) | 2025-11-07 |
| CN119173535A (zh) | 2024-12-20 |
| CL2024002620A1 (es) | 2025-01-03 |
| JP7712496B2 (ja) | 2025-07-23 |
| AR128688A1 (es) | 2024-06-05 |
| US20250084178A1 (en) | 2025-03-13 |
| TW202340243A (zh) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010646A (es) | Anticuerpos anti-cd39 y uso de los mismos. | |
| CO2021003724A2 (es) | Proteínas de fijación a sirpα y métodos de uso de estas | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| MX2020001270A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39. | |
| EP3908559A4 (en) | ACTIVATION AND USE OF NATURAL PUZZOLAN | |
| MX2021007845A (es) | Anticuerpos contra il-4ra humano y uso de los mismos. | |
| EP4289861A4 (en) | Antibodies against human tslp and use thereof | |
| CO2023012821A2 (es) | Anticuerpos anti-nectina-4 y usos de los mismos | |
| AR117220A1 (es) | Métodos de expansión ex vivo de células asesinas naturales y sus usos | |
| MX2023001792A (es) | Metodos y composiciones para estimular los linfocitos t gamma delta. | |
| TWD194692S (zh) | 加濕器 | |
| AR121390A1 (es) | Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano | |
| CO2021007060A2 (es) | Péptidos inmunogénicos con motivos de oxidorreductasa mejorados | |
| MX2024012582A (es) | Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso | |
| MX2023002411A (es) | Celulas inmunitarias modificadas para fibrosis e inflamacion. | |
| CO2022005889A2 (es) | Derivados terapéuticos de interleucina-22 | |
| CO2025006500A2 (es) | Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas | |
| CL2022001546A1 (es) | Formulaciones líquidas de tasimelteón y métodos para su uso | |
| JOP20220206A1 (ar) | الخلايا التائية واستخداماتها | |
| UY39337A (es) | Anticuerpos anti-abeta | |
| ECSP20063338A (es) | Suplemento de cutícula para producción vegetal | |
| CO2023010689A2 (es) | Anticuerpos y usos de estos | |
| HRP20251630T1 (hr) | Kombinirana antitumorska terapija koja obuhvaća anti-cd19 protutijelo i gama-delta t stanice | |
| CR20250226A (es) | Anticuerpo anti-trem2 y usos del mismo |